乳腺癌免疫疗法：当前与未来策略
Immunotherapy for Breast Cancer: Current and Future Strategies.
作者信息
Williams Austin D, Payne Kyle K, Posey Avery D, Hill Christine, Conejo-Garcia Jose, June Carl H, Tchou Julia
机构信息
Department of Surgery, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Boulevard, 10th floor South, Philadelphia, PA 19104, USA.
The Wistar Institute, Philadelphia, PA, USA.
出版信息
Curr Surg Rep. 2017 Dec;5. doi: 10.1007/s40137-017-0194-1. Epub 2017 Oct 10.
Abstract
PURPOSE OF REVIEW
The breast tumor microenvironment is immunosuppressive and is increasingly recognized to play a significant role in tumorigenesis. A deeper understanding of normal and aberrant interactions between malignant and immune cells has allowed researchers to harness the immune system with novel immunotherapy strategies, many of which have shown promise in breast cancer. This review discusses the application of immunotherapy to the treatment of breast cancer.
RECENT FINDINGS
Both basic science and clinical trial data are rapidly developing in the use of immunotherapy for breast cancer. The current clinical trial landscape includes therapeutic vaccines, immune checkpoint blockade, antibodies, cytokines, and adoptive cell therapy.
SUMMARY
Despite early failures, the application of immunotherapeutic strategies to the treatment of breast cancer holds promise.
摘要
综述目的
乳腺肿瘤微环境具有免疫抑制作用，并且越来越被认为在肿瘤发生中起重要作用。对恶性细胞与免疫细胞之间正常和异常相互作用的更深入理解，使研究人员能够利用新型免疫治疗策略来调控免疫系统，其中许多策略已在乳腺癌治疗中显示出前景。本文综述了免疫疗法在乳腺癌治疗中的应用。
最新发现
在乳腺癌免疫治疗的应用方面，基础科学和临床试验数据都在快速发展。当前的临床试验包括治疗性疫苗、免疫检查点阻断、抗体、细胞因子和过继性细胞治疗。
总结
尽管早期有失败案例，但免疫治疗策略在乳腺癌治疗中的应用仍具有前景。
相似文献
1
Immunotherapy for Breast Cancer: Current and Future Strategies.乳腺癌免疫疗法：当前与未来策略
Curr Surg Rep. 2017 Dec;5. doi: 10.1007/s40137-017-0194-1. Epub 2017 Oct 10.
2
Chimeric antigen receptor-based immunotherapy in breast cancer: Recent progress in China.嵌合抗原受体免疫疗法在乳腺癌中的研究进展：中国的最新进展。
Cancer. 2024 Apr 15;130(S8):1378-1391. doi: 10.1002/cncr.35096. Epub 2023 Nov 11.
3
Current and future immunotherapeutic approaches in pancreatic cancer treatment.当前和未来在胰腺癌治疗中的免疫治疗方法。
J Hematol Oncol. 2024 Jun 4;17(1):40. doi: 10.1186/s13045-024-01561-6.
4
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.胶质母细胞瘤免疫治疗：现有策略的系统评价及进展展望。
Int J Mol Sci. 2023 Oct 10;24(20):15037. doi: 10.3390/ijms242015037.
5
From promise to progress: the dynamic landscape of glioblastoma immunotherapy.从承诺到进展：胶质母细胞瘤免疫治疗的动态景观。
Drug Discov Today. 2024 Nov;29(11):104188. doi: 10.1016/j.drudis.2024.104188. Epub 2024 Sep 20.
6
Immunotherapy of glioblastoma: Recent advances and future prospects.胶质母细胞瘤的免疫治疗：最新进展与未来展望。
Hum Vaccin Immunother. 2022 Nov 30;18(5):2055417. doi: 10.1080/21645515.2022.2055417. Epub 2022 Mar 28.
7
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.新兴免疫疗法在晚期透明细胞肾细胞癌中的应用。
Cells. 2023 Dec 22;13(1):34. doi: 10.3390/cells13010034.
8
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.黑色素瘤研究的未来展望：“黑色素瘤桥梁”会议报告。那不勒斯，2015年12月1日至4日
J Transl Med. 2016 Nov 15;14(1):313. doi: 10.1186/s12967-016-1070-y.
9
Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.溶瘤病毒联合癌症免疫治疗：开创新一代癌症治疗。
Front Immunol. 2020 Apr 28;11:683. doi: 10.3389/fimmu.2020.00683. eCollection 2020.
10
Cancer immunotherapy beyond immune checkpoint inhibitors.免疫检查点抑制剂之外的癌症免疫疗法。
J Hematol Oncol. 2018 Jan 12;11(1):8. doi: 10.1186/s13045-017-0552-6.
引用本文的文献
1
Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells.乳腺癌与肿瘤微环境：免疫细胞的关键作用
Curr Oncol. 2025 Feb 28;32(3):143. doi: 10.3390/curroncol32030143.
2
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.最大化CAR-T细胞免疫疗法治疗癌症疗效的输注与给药策略。
Exp Hematol Oncol. 2024 Jul 26;13(1):70. doi: 10.1186/s40164-024-00542-2.
3
Synthetic biology approaches for improving the specificity and efficacy of cancer immunotherapy.合成生物学方法提高癌症免疫治疗的特异性和疗效。
Cell Mol Immunol. 2024 May;21(5):436-447. doi: 10.1038/s41423-024-01153-x. Epub 2024 Apr 11.
4
Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer.针对 HER2 阳性乳腺癌患者的创新治疗方法。
Cancer Treat Res. 2023;188:237-281. doi: 10.1007/978-3-031-33602-7_10.
5
The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions.肿瘤相关抗原HER2/neu在肿瘤发展中的作用及其在治疗中的不同应用方法：众多选择与未来方向
Cancers (Basel). 2022 Dec 14;14(24):6173. doi: 10.3390/cancers14246173.
6
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors.三阴性乳腺癌中的免疫疗法：超越检查点抑制剂
NPJ Breast Cancer. 2022 Nov 9;8(1):121. doi: 10.1038/s41523-022-00486-y.
7
Peptide-Based Vaccines in Clinical Phases and New Potential Therapeutic Targets as a New Approach for Breast Cancer: A Review.基于肽的疫苗在乳腺癌治疗中的临床阶段及新潜在治疗靶点：综述
Vaccines (Basel). 2022 Aug 3;10(8):1249. doi: 10.3390/vaccines10081249.
8
Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions.人表皮生长因子受体2低表达乳腺癌的靶向治疗方法：当前实践与未来方向
Cancers (Basel). 2022 Aug 3;14(15):3774. doi: 10.3390/cancers14153774.
9
Immunological significance of prognostic markers for breast cancer based on alternative splicing.基于可变剪接的乳腺癌预后标志物的免疫学意义
Am J Transl Res. 2022 Jun 15;14(6):4229-4250. eCollection 2022.
10
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.嵌合抗原受体T细胞：概念、应用、局限性及建议解决方案概述
Front Bioeng Biotechnol. 2022 Jun 22;10:797440. doi: 10.3389/fbioe.2022.797440. eCollection 2022.
本文引用的文献
1
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.双重血管生成素-2 和 VEGFA 抑制引发抗肿瘤免疫，这种免疫可被 PD-1 检查点阻断增强。
Sci Transl Med. 2017 Apr 12;9(385). doi: 10.1126/scitranslmed.aak9670.
2
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.IIa类组蛋白去乙酰化酶抑制通过抗肿瘤巨噬细胞减少乳腺肿瘤和转移。
Nature. 2017 Mar 16;543(7645):428-432. doi: 10.1038/nature21409. Epub 2017 Mar 8.
3
Transient Treg depletion enhances therapeutic anti-cancer vaccination.一过性 Treg 耗竭增强了抗肿瘤的免疫治疗效果。
Immun Inflamm Dis. 2016 Nov 21;5(1):16-28. doi: 10.1002/iid3.136. eCollection 2017 Mar.
4
Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.利用嵌合抗原受体工程化T细胞靶向实体瘤中异常的αvβ6整合素表达
Mol Ther. 2017 Jan 4;25(1):259-273. doi: 10.1016/j.ymthe.2016.10.012.
5
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.Fc修饰的嵌合单克隆抗体玛格妥昔单抗（MGAH22）在HER2阳性晚期实体瘤患者中的首次人体1期研究。
Ann Oncol. 2017 Apr 1;28(4):855-861. doi: 10.1093/annonc/mdx002.
6
Tumour-associated macrophages as treatment targets in oncology.肿瘤相关巨噬细胞作为肿瘤治疗的靶点。
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416. doi: 10.1038/nrclinonc.2016.217. Epub 2017 Jan 24.
7
SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells.SATB1的表达调控肿瘤反应性T细胞中PD-1的表观遗传抑制。
Immunity. 2017 Jan 17;46(1):51-64. doi: 10.1016/j.immuni.2016.12.015.
8
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 DCIS Independent of Route: Results of Randomized Selection Design Trial.树突状细胞疫苗接种增强免疫反应，并独立于途径诱导 HER2 DCIS 消退：随机选择设计试验的结果。
Clin Cancer Res. 2017 Jun 15;23(12):2961-2971. doi: 10.1158/1078-0432.CCR-16-1924. Epub 2016 Dec 13.
9
Immune Blockade Inhibition in Breast Cancer.乳腺癌中的免疫阻断抑制
Anticancer Res. 2016 Nov;36(11):5607-5622. doi: 10.21873/anticanres.11145.
10
The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis.髓源性抑制细胞在实体瘤患者中的作用：一项荟萃分析。
PLoS One. 2016 Oct 25;11(10):e0164514. doi: 10.1371/journal.pone.0164514. eCollection 2016.
Zotero 插件